ATE483722T1 - Antikrebs-cyclopentaag chinazoline-derivate - Google Patents

Antikrebs-cyclopentaag chinazoline-derivate

Info

Publication number
ATE483722T1
ATE483722T1 AT02755281T AT02755281T ATE483722T1 AT E483722 T1 ATE483722 T1 AT E483722T1 AT 02755281 T AT02755281 T AT 02755281T AT 02755281 T AT02755281 T AT 02755281T AT E483722 T1 ATE483722 T1 AT E483722T1
Authority
AT
Austria
Prior art keywords
alkyl
cyclopentaag
cancer
halogenoalkyl
cyanoalkyl
Prior art date
Application number
AT02755281T
Other languages
English (en)
Inventor
Vassilios Bavetsias
Ann Jackman
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121151A external-priority patent/GB0121151D0/en
Priority claimed from GB0129387A external-priority patent/GB0129387D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of ATE483722T1 publication Critical patent/ATE483722T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02755281T 2001-08-31 2002-08-30 Antikrebs-cyclopentaag chinazoline-derivate ATE483722T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds
GB0129387A GB0129387D0 (en) 2001-12-07 2001-12-07 Anti-cancer compounds
US34025301P 2001-12-18 2001-12-18
PCT/GB2002/003979 WO2003020748A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds

Publications (1)

Publication Number Publication Date
ATE483722T1 true ATE483722T1 (de) 2010-10-15

Family

ID=27256270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02755281T ATE483722T1 (de) 2001-08-31 2002-08-30 Antikrebs-cyclopentaag chinazoline-derivate

Country Status (15)

Country Link
US (6) US7297701B2 (de)
EP (3) EP2332962A1 (de)
JP (1) JP4328202B2 (de)
KR (2) KR20100043294A (de)
AT (1) ATE483722T1 (de)
AU (1) AU2002321576B2 (de)
BR (1) BRPI0212215B8 (de)
CA (1) CA2458813C (de)
CY (1) CY1111078T1 (de)
DE (1) DE60237902D1 (de)
DK (1) DK1421105T3 (de)
MX (1) MXPA04001905A (de)
PT (1) PT1421105E (de)
WO (1) WO2003020748A1 (de)
ZA (1) ZA200401587B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE483722T1 (de) * 2001-08-31 2010-10-15 Btg Int Ltd Antikrebs-cyclopentaag chinazoline-derivate
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
JP5564249B2 (ja) 2006-06-23 2014-07-30 アレシア・バイオセラピューティクス・インコーポレーテッド 癌に関与するポリヌクレオチド配列およびポリペプチド配列
WO2009115776A1 (en) * 2008-03-18 2009-09-24 Btg International Limited Cyclopenta[g]quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
KR20130056887A (ko) * 2010-07-19 2013-05-30 오닉스 파마슈티컬즈, 인크. 시클로펜타퀴나졸린의 합성
JP2014513663A (ja) * 2010-12-22 2014-06-05 オニックス ファーマシューティカルズ,インコーポレイティド 効率的なペプチドカップリングおよびシクロペンタ[g]キナゾリン3ナトリウム塩の合成および単離でのそれらの使用
JP6294221B2 (ja) 2011-03-31 2018-03-14 アー・デー・ツェー・セラピューティクス・エス・アー 腎臓関連抗原1に対する抗体およびその抗原結合性フラグメント
TR201908872T4 (tr) 2012-01-09 2019-07-22 Adc Therapeutics Sa Üçlü negatif meme kanserini tedavi etmek için ajanlar.
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0031237B1 (de) 1979-12-19 1984-10-17 National Research Development Corporation Chinazolinderivate, Verfahren zu ihrer Herstellung, sie enthaltende Zusammensetzungen und ihre Verwendung als Anti-Krebs-Mittel
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
JPH1166841A (ja) * 1997-08-22 1999-03-09 Mitsubishi Electric Corp 半導体記憶装置
KR100303775B1 (ko) * 1998-10-28 2001-09-24 박종섭 디디알 에스디램에서 데이터스트로브신호를 제어하기 위한 방법및 장치
GB9904275D0 (en) 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP3416083B2 (ja) * 1999-08-31 2003-06-16 株式会社日立製作所 半導体装置
JP2002007200A (ja) * 2000-06-16 2002-01-11 Nec Corp メモリ制御装置及び動作切替方法並びにインターフェース装置、半導体集積チップ、記録媒体
ATE483722T1 (de) * 2001-08-31 2010-10-15 Btg Int Ltd Antikrebs-cyclopentaag chinazoline-derivate
PT1420809E (pt) 2001-08-31 2012-01-03 Btg Int Ltd Utilização de derivados de ciclopenta[g]quinazolina para tratamento de cancro
KR100568546B1 (ko) * 2004-10-19 2006-04-07 삼성전자주식회사 메모리 시스템, 반도체 메모리 장치, 및 이 시스템과장치의 출력 데이터 스트로우브 신호 발생 방법
KR100755371B1 (ko) * 2005-05-03 2007-09-04 삼성전자주식회사 반도체 메모리 장치 및 이 장치의 데이터 스트로우브 신호발생방법

Also Published As

Publication number Publication date
EP1421105A1 (de) 2004-05-26
BR0212215A (pt) 2004-09-21
US8486955B2 (en) 2013-07-16
DE60237902D1 (de) 2010-11-18
US20100216824A1 (en) 2010-08-26
CY1111078T1 (el) 2015-06-11
EP2311850A1 (de) 2011-04-20
US7297701B2 (en) 2007-11-20
US8552016B2 (en) 2013-10-08
BRPI0212215B1 (pt) 2019-02-19
EP2332962A1 (de) 2011-06-15
US7705006B2 (en) 2010-04-27
KR20100043294A (ko) 2010-04-28
MXPA04001905A (es) 2005-04-19
US20090023760A1 (en) 2009-01-22
AU2002321576B2 (en) 2008-09-11
PT1421105E (pt) 2010-12-07
KR100983962B1 (ko) 2010-09-27
BRPI0212215B8 (pt) 2021-07-27
DK1421105T3 (da) 2010-11-29
US20100056551A1 (en) 2010-03-04
CA2458813A1 (en) 2003-03-13
US20100273817A1 (en) 2010-10-28
JP4328202B2 (ja) 2009-09-09
KR20040044511A (ko) 2004-05-28
US7863284B2 (en) 2011-01-04
JP2005509600A (ja) 2005-04-14
CA2458813C (en) 2011-11-01
US20080015206A1 (en) 2008-01-17
US20040242606A1 (en) 2004-12-02
WO2003020748A1 (en) 2003-03-13
EP1421105B1 (de) 2010-10-06
US8063056B2 (en) 2011-11-22
ZA200401587B (en) 2005-05-25

Similar Documents

Publication Publication Date Title
CY1111078T1 (el) Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων
CY1112143T1 (el) Χρηση παραγωγων kykλοπenta[g]kinαζολινης για θεραπεια καρκινου
WO2002018383A3 (en) Aza heterocyclic derivatives and their therapeutic use
NO983970D0 (no) Tricykliske forbindelser, deres fremstilling og anvendelse
EP1447405A4 (de) Chinolin- oder chinazolinderivate, die die autophosphorylierung von rezeptoren für den fibroblastenwachstumsfaktor hemmen
ATE416176T1 (de) Kondensierte chinolinderivate und deren anwendung
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
PT1122244E (pt) Compostos de uracilo e seu uso
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
EP0979821A4 (de) Trizyklische verbindungen
WO2002044153A8 (en) 4-6-diphenyl pyridine derivatives as antiinflammatory agents
IE872317L (en) Dihydropyridine anti-allergic and anti-inflammatory agents
ATE261445T1 (de) Neue 1,8-naphtyridin-2(1h)-on-derivate
HUP0401588A2 (hu) Rákellenes és proliferáció elleni hatású indeno[1,2-c]pirazol-4-on-származékok és ezeket tartalmazó gyógyszerkészítmények
WO2009135673A3 (en) Compounds with glycidic structure active in the therapy of systemic and local inflammation
BR0114812A (pt) Derivados de 2-pirimidinilóxi-n-aril-benzilamina, seus processos de preparo e uso
DK640889D0 (da) Fenylderivater med antidiabetisk, isaer hypoglykaemisk virkning
IL157594A0 (en) Carbamate compounds for use in preventing or treating anxiety disorders
WO2005115984A3 (en) Large conductance calcium-activitated k channel opener
EP1340748A4 (de) Chinazolinderivate und -arzneimittel
PE20010649A1 (es) Derivados de antranilamida de piperidinas 1,4-di-sustituidas como antagonistas muscarinicos
TR200200969T2 (tr) Karbonilamino türevlerinin CNS bozukluklarına karşı kullanılması
BRPI0418375A (pt) derivados de diaza-espiropiperidina
FI902775A0 (fi) Aryloxi-, aryltio-, heteroaryloxi-, heteroaryltio-alkylenderivat av aminer.
DE602006020458D1 (de) Carbonsäureamidverbindung und deren verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1421105

Country of ref document: EP